Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Michael N Liebman


Michael N Liebman

dagv

Biography

Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University. Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics. He serves on 14 scientific advisory boards and is on the Board of Directors of the Nathaniel Adamczyk Foundation for Pediatric ARDS and is an Advisor to the American Heart Association Science and Technology Accelerator. Michael is Chair of the Informatics Program of the PhRMA Foundation and also Chair of its program in Translational Medicine and Therapeutics and a member of the PhRMA Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics and the International Park for Translational Biomedicine (Shanghai). He is an Invited Professor at the Shanghai Center for Bioinformatics Technology. His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling patient and disease stratification, and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life.

Abstract

Abstract : Unmet clinical need: Lost in the translational